ClinicalTrials.gg
CompletedNCT04999007Updated Oct 13, 2026

Artificial Intelligence Assists Surgeons' Decision Making

An interventional study of Artificial intelligence algorithm in Rectal Cancer, sponsored by Jichao Qin. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Jichao Qin · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
872
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 463 studies in Rectal Neoplasms with a site in China — 228 open to participants now, 267 under way, 42 of them phase 3. Rectal Neoplasms · China.

Enrollment
15th of 373
872 · median 100
Started
2021
with 36 others
No phase
133 of 463
58 open now
Registered
179th of 463
by date

Among the 463 studies in Rectal Neoplasms with a site in China, this one is the 15th largest by enrollment of the 373 interventional ones that give a count, is one of 37 that started in 2021, is one of 133 with no phase, and was the 179th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

228 of the 463 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

223 more — sign in →

All 228 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study will evaluate whether artificial intelligence technique reduces the temporary ileostomy rate in patients with rectal cancer who receive anterior resection.

Read the detailed description

Anastomotic leakage is a serious and life-threatening complication after anterior resection in patients with rectal cancer, and temporary ileostomy was introduced to reduce the serious consequences due to anastomotic leakage. However, whether a temporary ileostomy is applied in the surgery depends on the surgeon's experience, and there are no clinical guidelines to follow. Recently, artificial intelligence has widely been applied in medical field and produced some exciting results, and we have developed a high-performance artificial intelligence model based on 2369 rectal cancer patients, which showed good discrimination of anastomotic leakage and may reduce the temporary ileostomy rate. Hence, this randomized controlled trail will evaluate the artificial intelligence model for guiding surgical decision-making of performing a temporary ileostomy in patients with rectal cancer who receive anterior resection.

03

Conditions studied

  • Rectal Cancer

Keywords

  • artificial intelligence,
  • rectal cancer
  • temporary ileostomy
  • anastomotic leakage
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged older than 18 years and younger than 85 years.
  2. Primary rectal adenocarcinoma confirmed by preoperative pathology result.
  3. Expected curative resection via total mesorectal excision procedure.
  4. (ASA) class I, II, or III.
  5. Written .

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Severe mental disorder or language communication disorder.
  3. Hartmann surgery or colostomy is performed intraoperatively.
  4. Interrupted of surgery for more than 30 minutes due to any cause.
  5. Malignant tumors with other organs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
872 participants (actual)

Study arms

  • No intervention
    Control

    Whether the patients in the control arm will receive a temporary ileostomy depends on surgeons' experience.

  • Experimental
    Intervention

    Whether the patients in the intervention arm will receive a temporary ileostomy depends on the risk of anastomotic leakage calculated by the artificial intelligence algorithm.

    Other: Artificial intelligence algorithm

Interventions

  • OtherArtificial intelligence algorithm

    Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.

06

What researchers measure

Primary outcomes

  1. The rate of temporary ileostomy.

    Time frame: Intraoperative period

  2. The morbidity of anastomotic leakage.

    The diagnosis of anastomotic leakage is determined when the passage of fecal material from pelvic drainage tube or the water-soluble contrast agent enema and extra-rectal imaging. Alternatively, anastomotic leakage can be diagnosed when the integrity of the anastomosis is interrupted or the appearance of pelvic abscess next to the anastomosis by computerized tomography (CT) examination or secondary surgical exploration.

    Time frame: 30 days

07

Study locations

1 site
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430000, China
08

References and documents

Publications

  • Shao S, Li Y, Li J, Liu L, Zeng Y, Song C, Huang W, Mu L, Qin J. Machine learning model-guided selective use of temporary diverting ileostomy in rectal cancer surgery: a randomized controlled trial. Nat Commun. 2026 May 25;17(1):6802. doi: 10.1038/s41467-026-73565-4. PubMed 42185305 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Mar 2025, 42 months.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's 42 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2025 → Mar 2025 and completion Oct 2025 → Mar 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2021
First posted
Aug 10, 2021
StartActual
Sep 2, 2021
Primary completionActual
Mar 17, 2025was Sep 2025
CompletionActual
Mar 17, 2025was Oct 2025
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 13, 2026
Primary completion
Sep 2025→Mar 17, 2025 (actual)
Oct 13, 2026
Study completion
Oct 2025→Mar 17, 2025 (actual)
Oct 13, 2026
Enrollment
616 (estimated)→872 (actual)
Oct 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42185305 ↗
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42185305 ↗
    Primary completion Sep 2025→Mar 17, 2025 (now actual)
    Study completion Oct 2025→Mar 17, 2025 (now actual)
    Enrollment 616 (estimated)→872 (actual)
    + 4 other changes: index terms, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04999007
Lead sponsor
Jichao Qin
Responsible party
Jichao Qin (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Aug 10, 2021
Start date
Sep 2, 2021
Primary completion
Mar 17, 2025
Completion
Mar 17, 2025
Last update
Oct 13, 2026

Study contacts

Jichao Qin, MD
principal investigator · Huazhong University of Science and Technology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion